

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS IX LLC,

Petitioner

v.

BRISTOL-MYERS SQUIBB PHARMA COMPANY

Patent Owner

IPR2015-_____

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES
THEREOF AS FACTOR XA

**PETITION FOR INTER PARTES REVIEW OF
U.S. PATENT NO. 6,967,208**

TABLE OF CONTENTS

TABLE OF AUTHORITIES	iv
LIST OF EXHIBITS.....	v
I. Introduction.....	1
II. Grounds for Standing.....	1
III. Mandatory Notices	1
A. Real Party-In-Interest	1
B. Related Matters	2
C. Lead and Back-Up Counsel, and Service Information.....	3
IV. Payment of Fees	3
V. Identification of Challenge.....	3
A. Overview of the '208 Patent.....	3
1. The '208 Specification	3
2. The '208 Claims.....	5
3. The '208 Prosecution History	10
4. The Certificate of Correction	12
B. Claim Construction of Challenged Claims.....	13
1. "1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl-4,5,6,7-tetrahydro-1Hpyrazolo-[3,4-c]pyridine-3-carboxamide"	14
2. "Pharmaceutically acceptable salt"	14
3. Claims for Which Review Is Requested	15
4. Statutory Grounds of Challenge.....	15
C. Overview of the Cited Art.....	15
1. PCT Publication No. WO 00/39131 (Ex. 1003).....	16
2. U. S. Patent 6,413,980 (Ex. 1004)	17
D. Level of Skill in the Art.....	19
VI. Detailed Explanation of the Challenge	20

A. Ground 1: PCT Published Application WO 00/39131 to Fevig et al. (“ <i>Fevig I</i> ”) (Ex. 1003) anticipates claims 1-13, 20-27, and 34-61 of US 6,967,208 under 35 U.S.C. § 102(b).....	20
1. Anticipation of Claim 13 by <i>Fevig I</i>	22
2. Anticipation of Claim 8 by <i>Fevig I</i>	27
3. Anticipation of Claim 1 by <i>Fevig I</i>	28
4. Anticipation of Claim 2 by <i>Fevig I</i>	34
5. Anticipation of Claim 3 by <i>Fevig I</i>	35
6. Anticipation of Claim 4 by <i>Fevig I</i>	35
7. Anticipation of Claim 5 by <i>Fevig I</i>	36
8. Anticipation of claim 6 by <i>Fevig I</i>	36
9. Anticipation of Claim 7 by <i>Fevig I</i>	37
10. Anticipation of claims 9-12, 20-27, and 34-61 by <i>Fevig I</i>	38
B. Ground 2: U.S. Patent 6,413,980 to Fevig et. al (“ <i>Fevig II</i> ”) (Ex. 1004) anticipates claims 1-13, 20-27, and 34-61 of U.S. 6,967,208 under 35 U.S.C. § 102(e).....	38
1. Anticipation of Claim 13 by <i>Fevig II</i>	39
2. Anticipation of Claim 8 <i>Fevig II</i>	43
3. Anticipation of Claim 1-7 <i>Fevig II</i>	44
4. Anticipation of claims 9-12, 20-27 and 34-61.	51
C. Grounds 3 and 4: <i>Fevig I</i> and <i>Fevig II</i> , each in its own right, renders the challenged claims of the ‘208 Patent obvious under 35 U.S.C. 103(a).....	54
D. Secondary Considerations of Non-Obviousness Do Not Rebut the Prima Facie Case of Obviousness	58
VII. Conclusion	60
CERTIFICATE OF SERVICE.....	61

TABLE OF AUTHORITIES

Cases

<i>App. of Susi</i> 440 F.2d 442; 169 U.S.P.Q. 423 (CCPA, 1971).....	21, 57
<i>Application of Ruff</i> 256 F.2d 590 (CCPA 1958)	21, 27, 34, 44
<i>Atlas Powder Co. v. Ireco, Inc.</i> 190 F.3d 1342, 51 U.S.P.Q.2d (BNA) 1943 (Fed. Cir. 1999).....	21, 27, 34, 44
<i>Calloway Golf Company v. Acushnet Company</i> 576 F.3d 1331 (Fed. Cir. 2009).....	6
<i>In re Swanson</i> 540 F.3d 1368 (Fed. Cir. 2008)	19
<i>Merck v Biocraft Labs.</i> 874 F.2d 804; 10 U.S.P.Q. 2d 1843 (Fed. Cir. 1989).....	57
<i>Ruiz v. A.B. Chance Co.</i> 234 F.3d 654 (Fed. Cir. 2000).....	59
<i>Upsher-Smith Labs., Inc. v. PamLab, L.L.C.</i> 412 F.3d 1319 (Fed. Cir. 2005).....	30
<i>Verdegaal Bros. v. Union Oil Co. of California</i> 814 F.2d 628 (Fed. Cir. 1987).....	20
Statutes	
35 U.S.C. 102(e)(2)	18
35 U.S.C. 303(a)	19
Regulations	
37 C.F.R. § 42.100(b)	14

LIST OF EXHIBITS

Exhibit 1001	U.S. 6,967,208 to Pinto et. al, titled, “Lactam Containing Compounds and Derivatives Thereof as Factor Xa Inhibitors,” filed on September 17, 2002, and issued on November 22, 2005 (“the ’208 Patent”).
Exhibit 1002	Excerpts from the File History of U.S. Patent No. 6,967,208.
Exhibit 1003	Published PCT Application WO 00/39131 titled Nitrogen Containing Heterobicycles as Factor Xa Inhibitors, published on July 6, 2000 (“ <i>Fevig I</i> ”).
Exhibit 1004	U.S. Patent 6,413,980 to Fevig et. al, titled Nitrogen Containing Heterobicycles as Factor Xa Inhibitors, filed on December 22, 1999. (“ <i>Fevig II</i> ”)
Exhibit 1005	Excerpts from the File History of U.S. Patent 6,413,980
Exhibit 1006	Published PCT Application WO 95/01980 titled Bicyclic Tetrahydro Pyrazolopyridines, filed July 3, 1993. (<i>Duplantier</i>)
Exhibit 1007	Reserved
Exhibit 1008	Expert Declaration of George Burton
Exhibit 1009	Prescribing Information– Eliquis FDA Label

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.